Αξιολόγηση της αγοράς των γενοσήμων φαρμάκων στην Ελλάδα.
Evaluation of the generic medicines market in Greece
View/
Abstract
INTRODUCTION: Due to the economic crisis, there is a globally increased interest about the use of generics medicines. The aim is to reduce the budget of pharmaceutical cost. In Greece, generic drugs have sparked debates that are based on conflicting opinions, mainly about their therapeutic worthiness compared to the originals and their low price as well.
AIM: The aim of the current study is to investigate and evaluate the market of generics in Greece. In particular, the concept of generic drugs, their characteristics and the generic market will be explored and the reasons to use them will be presented.
MATERIAL AND METHOD: Data were collected from the database of IMS Health company in excel file. They concern sales of generic medicines in the third quarter of 2001 until the third quarter of 2013. For this period the total volume of generic sales is reflected for the 4 major therapeutic categories (antidepressants, antipsychotics, antidiabetics and gastroprotective drugs). The generic medicines’ use and their market penetration have been studied, not only in Greece but also in England, Germany and France. The accrued results were compared in order to draw conclusions. Data statistical analysis was performed by the statistical program Stata (ver. 12).
RESULTS: In Greece the majority of sales accrued by the antidepressants and antidiabetic drugs, that hold the highest sales in the total pharmaceutical market. The gastroprotective generic medicines were the lowest part of sales on the total generic market. Moreover, Greece is low ranked in the generic market compared to Great Britain and Germany. The antidiabetic and antidepressant generic medicines hold the highest sales among the rest of the under study countries. As for the generic market penetration is appeared to have an upward progress.
CONCLUSIONS: In the current study it was obvious that, due to the economic crisis, one of the main objectives is the reduction of public pharmaceutical cost. So the adoption of generics is increasingly supported. Although the penetration of generics in the Greek market is still low, it is expected to be boosted following the international trends. Finally it must be underlined that in Greece there is a lack of continuity in pharmaceutical policies, poor coordination and distortion of economic incentives.
Postgraduate Studies Programme
Οικονομικά και Διοίκηση της ΥγείαςDepartment
Σχολή Οικονομικών, Επιχειρηματικών και Διεθνών Σπουδών. Τμήμα Οικονομικής ΕπιστήμηςNumber of pages
132Language
GreekCollections
Except where otherwise noted, this item's license is described as
Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 4.0 Διεθνές
Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 4.0 Διεθνές